

Human Milk Oligosaccharides (HMO) Market to Show Exponential Growth by 2028 | Worldwide Value \$332.6 Million

PORTLAND, 5933 NE WIN SIVERS DRIVE, #205, OR 97220, UNITED STATES, September 4, 2023

/EINPresswire.com/ -- According to a new report published by Allied Market Research, titled, "[Human Milk Oligosaccharides Market](#) by Type, Application, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021–2028," the global human milk oligosaccharides (HMO) market size was valued at \$125.9 million in 2020, and is estimated to reach \$332.6 million by 2028, registering a CAGR of 14.1% from 2021 to 2028.



Human milk oligosaccharide (HMO) is a prebiotic that aids in the maintenance of human gut health. It stimulates bacterial growth, particularly in the Bifidobacteriagenus, which aids in metabolic activity. Owing to its antimicrobial and prebiotic properties, it can be used in a variety of foods, including pharmaceutical and medicinal foods as well as infant formulas.

“

Rise in number of health-conscious consumers, increase in awareness of the benefits of HMOs especially for infants, entry of new market players.”

Allied Market Research

HMOs are sugars, which are the third most abundant solid nutrients in human breast milk after lactose and fats. They improve and enhance infant health by promoting immune development, neurodevelopment, and digestion, and also have the potential to benefit adults. Some of the

nutritional effects of HMOs found in human milk can be recreated by commercially manufactured HMOs.

Request For PDF Before its Gone @ <https://www.alliedmarketresearch.com/request->

Fermented HMO allows infant formula manufacturers to produce formula that is more similar to human milk than ever before, allowing formula-fed babies to benefit from these important components of breast milk. Human milk oligosaccharides serve a variety of primary functions, including infection prevention, prebiotic effects, and sialic acid supply for brain growth. Infant formula made from bovine milk, that is cow milk, contains less oligosaccharides than human milk. Ash MOs are beneficial to the micro biome and immunity, key players are researching and developing new techniques, such as extracting HMO from cow milk using expensive techniques, or even generating them using microbes.

The rapid evolution of consumer preferences is one of the key factors driving innovation in the food & beverage industry. At present, the current Human Milk Oligosaccharides (HMO) market trends indicate that the demand for HMOs is expected to grow at a significant rate in the coming years, due to the steady rise in number of health-conscious people around the world as well as increase in awareness about the benefits of HMOs. Owing to rise in customer concerns about stable health and increase in the use of food supplements or dietary supplements, the Human Milk Oligosaccharides (HMO) market has witnessed exponential growth.

Get Your Report Customized @ <https://www.alliedmarketresearch.com/request-for-customization/12392>

Furthermore, over the last decade, a large number of players have gradually entered the global Human Milk Oligosaccharides (HMO) market, resulting in the availability of HMOs with a wide range of nutritional content through a variety of distribution channels. Another factor that has contributed to the popularity of HMOs in recent years is the digital boom, which has seen brands continue to promote their products via online sales channels such as e-mail marketing, social media, and newsletters. While the global Human Milk Oligosaccharides (HMO) market remains competitive, market participants are expected to concentrate on packaging, pricing, and marketing strategies to gain a competitive advantage in the current market landscape.

The introduction of new products is expected to reduce the impact of specific diseases such as diabetes and indigestion. Some major manufacturers have already started to offer products in specific health and wellness categories, such as digestion and cognitive enhancement. This trend is expected to take center stage and gain significant traction in the rapidly expanding functional food & beverage market, as well as significant brand equity, during the Human Milk Oligosaccharides (HMO) market forecast.

The third most abundant component of human milk is human oligosaccharides, which cannot be synthesized directly from human milk due to the donor group's scarcity. Currently, manufacturers use chemical and enzyme synthesis to produce human milk oligosaccharides. These methods necessitate a large investment of time and money, but the end result is relatively small.

Buy Now & Get Exclusive Discount on this Report @

<https://www.alliedmarketresearch.com/checkout-final/b3f0ba82511ff2a7908a719a09165925>

For example, expensive substrates such as glycosyl-transferases necessitate enzyme synthesis, which is one of the primary reasons for the high price of human milk oligosaccharides. Prebiotics, such as fructooligosaccharides and galactooligosaccharides, are used in infant formula to prevent the growth of pathogenic Escherichia coli bacteria. Consumption of these has been shown to improve infant gastrointestinal tract health by promoting the development of specific microorganisms in the intestinal micro flora. Infant formula manufacturers use these as a substitute for HMOs due to their low cost and widespread availability. As a result, these functionally equivalent alternatives to HMOs are severely limiting market growth.

Interested to Procure the Data? Inquire @ <https://www.alliedmarketresearch.com/purchase-enquiry/12392>

Product launches, mergers & acquisitions, joint ventures, and geographical expansions are the key strategies adopted by players in the Human Milk Oligosaccharides (HMO) industry. The key players operating in the Human Milk Oligosaccharides (HMO) industry include Abbott Laboratories, BASF S.E., Biosynth Carbosynth, Chr. Hansen Holding A/S, Dextra Laboratories Ltd., Dupont Nutrition & Biosciences, Elicityl S.A., Glycom A/S, Glycosyn, Inbiose NV, Medolac Laboratories, Neolacta Lifesciences Pvt. Ltd, Nestle Health Science, Royal DSM, and ZuChem.

Key findings of the study

The global Human Milk Oligosaccharides (HMO) market was valued at \$125.9 million in 2020, and is projected to reach \$332.6 million by 2028, registering a CAGR of 14.1% from 2021 to 2028.

Europe was the highest revenue contributor, accounting for \$45.3 million in 2020, and is estimated to reach \$124.1 million by 2028, with a CAGR of 14.6%.

By type, the 2'FL segment was the highest contributor to the market, with \$42.3 million in 2020, and is estimated to reach \$120.6 million by 2028, at a CAGR of 14.6% during the forecast period.

On the basis of application, the infant formula segment was the highest contributor to the market, with \$67.9 million in 2020, and is estimated to reach \$191.7 million by 2028, at a CAGR of 14.5% during the forecast period.

In Europe, the UK was the highest revenue contributor with \$12.5 million in 2020, and is estimated to reach \$37.5 Million by 2028, registering a CAGR of 15.4%.

Browse Related Reports:

[Vitamin E Market](#)

[Functional Beverages Market](#)

David Correa

Allied Analytics LLP

+1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/653632040>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.